Cargando…
Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies
BACKGROUND: Peritoneal mesothelioma (PeM) is a rare malignancy with a poor prognosis. Currently there is a lack of effective systemic therapies. Due to the rarity of PeM, it is challenging to study new treatment options. Off-label use of targeted drugs could be an effective approach. This scoping re...
Autores principales: | Dietz, M.V., van Kooten, J.P., Paats, M.S., Aerts, J.G.V.J., Verhoef, C., Madsen, E.V.E., Dubbink, H.J., von der Thüsen, J.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368826/ https://www.ncbi.nlm.nih.gov/pubmed/37453150 http://dx.doi.org/10.1016/j.esmoop.2023.101600 |
Ejemplares similares
-
Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
por: van Kooten, Job P, et al.
Publicado: (2022) -
Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study
por: de Boer, Nadine L., et al.
Publicado: (2019) -
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO
por: van Kooten, Job P, et al.
Publicado: (2022) -
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
por: de Boer, Nadine L, et al.
Publicado: (2019) -
Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
por: Dietz, Michelle V, et al.
Publicado: (2023)